Perspective
Dr. Scadden is a consultant and shareholder in Fate Therapeutics, a consultant for Genzyme and a Scientific Advisory Board Member for Hospira. All other authors state that they have no conflicts of interest.
Received: 15 December 2008; Revised: 12 January 2009; Accepted: 12 February 2009
10.1359/jbmr.090225 About DOI
Role of the Osteoblast Lineage in the Bone Marrow Hematopoietic Niches ![]() |
| Joy Y Wu 1, David T Scadden 2 3, Henry M Kronenberg 1 * |
| 1Endocrine Unit, Boston, Massachusetts, USA 2Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA 3Harvard Stem Cell Institute, Cambridge, Massachusetts, USA |
| email: Henry M Kronenberg (hkronenberg@partners.org) |
*Correspondence to Henry M Kronenberg, Address correspondence to: Henry M. Kronenberg, MD, Endocrine Unit, Massachusetts General Hospital, 50 Blossom Street, Thier 1101, Boston, MA 02114, USA
Dr. Scadden is a consultant and shareholder in Fate Therapeutics, a consultant for Genzyme and a Scientific Advisory Board Member for Hospira. All other authors state that they have no conflicts of interest.| First page of article |
![]() |
Received: 15 December 2008; Revised: 12 January 2009; Accepted: 12 February 2009
| Digital Object Identifier (DOI) |
10.1359/jbmr.090225 About DOI
Journal Information
Information for CONTRIBUTORS
Media
Journal Tools
- Sign up for eTOC Alerts
- Subscription Information
- Recommend to Librarian
Permissions - FAQ
- Contact Us
News RSS feed
ASBMR Resources




